Numinus completes legal harvest of psilocybe mushrooms
Numinus Bioscience's developments include harvesting its first flush of Psilocybe mushrooms at its Health Canada licensed facility.
VANCOUVER, BC — Numinus Wellness Inc., a healthcare company, has harvested the first legal flush of Psilocybe mushrooms in Canada by a public company under its Health Canada-issued Controlled Drugs and Substances Dealer’s Licence.
“The first harvest of legally grown Psilocybe mushrooms is a significant milestone for the whole industry” said Michael Tan, chief operating officer, in a prepared statement. “Now, we can progress with research and development of standardized cultivation, extraction, and testing methods and exploring product formulations to support safe, evidence-based, accessible psychedelic-assisted psychotherapy, as well as build a sequenced spore library.”
Dennis McKenna, renowned ethnopharmacologist, Co-founder of the Heffter Research Institute, Founder of the McKenna Academy of Natural Philosophy, and member of Numinus’ General Advisory Council, adds, “Mushrooms have been used in traditional medicine for literally thousands of years, and hence, they are just that much closer to these ancient traditions. Natural mushroom extracts are also likely to be far more affordable compared to synthetic psilocybin, and that is an important consideration when it comes to ensuring accessibility to this medicine which can be so beneficial to many people. Cost should not be a barrier to access these medicines, and the use of mushroom extracts will help ensure those who need them most can benefit from psilocybin therapies.”
Numinus also shared a recent amendment application to its Health Canada-issued Controlled Drugs and Substances Licence. The current licence permits testing, import and export, storage and distribution of MDMA, Psilocybin, Psilocin, DMT, and Mescaline as well as the undertaking of novel mycological research initiatives. The amendment will additionally permit the sale of Psilocybe mushroom fruiting bodies and extract for clinical research protocols and the development of standardized testing for additional psychedelic substances.